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S u m m a r y  
Calcification (CALC) is the most frequent cause of the clinical failure of bioprosthetic valves (BHV's). Controlled-release 
(paravalvar) administration of the anticalcification agent ethanehydroxydiphosphonate (EHDP), as either Na 2 EHDP or in combina- 
tion (1 : 1) with the less soluble CaEHDP, from a silicone rubber matrix (20% w/w  EHDP) was studied both in vitro and in vivo for 
the prevention of BHV CALC. Seventeen sheep (6-7 months old, male, Suffolk) underwent tricuspid valve replacement using 
Hancock I, 25 mm porcine aortic bioprostheses. BHV explant evaluation after 16-20 weeks revealed that two of the 7 control BHV 
were calcified (139 + 20.8/~g CaE+/mg of tissue), while none of the 9 BHV retrieved from animals receiving controlled release EHDP 
demonstrated CALC (4.41 + 1.09 pg Ca2+/mg of tissue). No adverse effects of EHDP on bone or calcium metabolism were noted. 
The cumulative percent of EHDP released per electron microprobe analysis was 40.4% + 9.68 (Na, CaEHDP) to 79.0% ± 4.82 
(Na2EHDP) in vivo compared to 35.7% ± 7.72 and 78.6 ± 11.1 in vitro, respectively. Assessment of the Young's modulus (Y) using 
thermomechanical analysis (TMA) revealed a 1.5-fold (Silastic Q7-4840) to 9.5-fold (Silastic 382) increase in Y following drug 
loading. The Y for explanted, Silastic Q7-4840 polymer matrices ranged from 2.84 × 10 4 tO 5.57 X 10 5 dyne/cm 2. In vitro osmotic 
related matrix swelling of the NaEEHDP loaded, unsealed matrices (20% w/w) after 75 days was minimized to a 35.8% increase in 
weight due to coincorporation of CaEHDP with Na2EHDP in a 1 : 1 ratio and was further reduced (22.2% increase in weight) by 
sealing 76% of the releasing surface, compared to NaEEHDP matrices which demonstrated a 414% and 141% increase in weight, 
respectively. 
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widely used as replacements for diseased cardiac 
valves since 1970 (Barnhart et al., 1982a; Schoen 
and Levy, 1984; Schoen, 1987). However, the 
principal failure mode of BHV is sterile degenera- 
tion due to calcification (CALC) (Schoen and 
Levy, 1984; Schoen, 1987; Milano et al., 1984; 
Schoen and Hobson, 1985a). Despite the impor- 
tance of this problem, the pathophysiology of 
BHV calcification is incompletely understood 
(Schoen et al., 1985b), and there are no satisfac- 
tory means for its prevention. 
BHV CALC has been investigated in experi- 
mental animals using orthotopic valve replace- 
ments or conduit-mounted valves in sheep and 
calves (Barnhart et al., 1982b; Levy et al., 1983a; 
Thurbrikar et al., 1983; Gallo et al., 1987), and 
subcutaneous implants in mice (Levy et al., 1983b), 
rats (Levy et al., 1983c and 1985a), and rabbits 
(Fishbein et al., 1982). The subcutaneous and cir- 
culatory models simulate many of the pathologic 
features of long-term clinical implants. 
Ethanehydroxydiphosphonate (EHDP) has 
been shown to effectively inhibit experimental 
BHV CALC (Levy et al., 1985b and c) but s.c. 
administration of EHDP to rats at doses greater 
than 15 mg/kg /day  (Levy et al., 1987a) resulted 
in adverse effects on overall somatic growth, bone 
development, and serum Ca 2+ levels. However, 
controlled release of EHDP from polymeric 
matrices coimplanted with BHV subdermally in 
rats prevented CALC without adverse effects by 
using minimal local doses [> 0.1 mg/kg/24 h] 
(Levy et al., 1985b and c). 
The purpose of the present study was to for- 
mulate EHDP controlled release matrices for im- 
plantation with orthotopic BHV in the circulation, 
assess their in vitro release, and in vivo efficacy 
and function. Thus, these experiments assessed: 
(1) the efficacy of the polymer-drug formulation 
with regard to inhibition of BHV CALC following 
tricuspid valve replacements in sheep, (2) the re- 
lease profile of EHDP from the implanted matrix 
comparing in vitro to in vivo release, (3) the 
changes in viscoelastic properties of the polymer 
matrix resulting from drug loading and circulatory 
implantation, and (4) the magnitude of osmotic- 
induced matrix expansion. 
Materials and Methods 
Polydimethylsiloxane (Silastic 382), Silastic Q7- 
4840 and reinforced dacron Q7-4840 sheeting 
(plain weave, 0.007 in thick) were provided by 
Dow Coming (Midland, MI). Disodium 1,1-hy- 
droxyethylidene diphosphonate (Na2EHDP) was 
provided by Norwich Eaton (Norwich, NY). The 
Na2114C]EHDP (spec. act. = 48.9/~Ci/mmol) and 
the calcium salt of EHDP were provided by Procter 
and Gamble, Inc. (Cincinatti, OH). Atom fight 
scintillation solution was obtained from New Eng- 
land Nuclear (Billerica, MA). 
Controlled release matrices 
Carrier-free radiolabelled Na2114C]EHDP, ap- 
propriately diluted with unlabelled Na2EHDP to 
yield a specific activity of 1830 dpm//~mol EHDP, 
was levigated into polymer formulations for de- 
termining in vitro release of NaEEHDP. For im- 
plants with calcium EHDP incorporated with 
Na2EHDP, a 1 : 1 ratio of the two salts was used 
at the same total weight percentages as below. 
Circular (i.d. = 25 mm, o.d. = 31 mm) controlled 
release matrices were formulated by levigating di- 
sodium EHDP (90-106 /~m particle size) into 
either Silastic 382 or Silastic Q7-4840 at a 20 or 30 
wt. % concentration. 
A typical circular controlled release matrix is 
shown in Fig. 1. Each circular implant was fabri- 
cated with a wall thickness of 3 mm. The height of 
the polymer-drug ring was 3.5 mm, and sealing of 
all the surfaces (76% of total available surface 
area) except the internal circumference with a 
non-drug-containing layer (500 /~m) of Silastic 
Q7-4840 or 382 resulted in a total initial releasing 
surface area of 2.75 cm 2. Formulations fabricated 
from Silastic 382 were catalyzed by adding 2 drops 
of the catalyst (stannous octanoate) to 2 g of total 
formulation and then compression-molded under 
2000 p.s.i, at room temperature in stainless-steel 
molds on a Carver Press equipped with heated 
platens (model C, Fred S. Carver, Inc., Meno- 
monee Falls, WI). Controlled release matrices 
fabricated from Silastic Q7-4840 were compres- 
sion-molded as above and heat-cured at 120°C 
Dacron-reinforced sheeting was thermally bonded 
(T = 120 o C) to the top and bottom surface of the 
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Fig. ]. A silicone rubber-EHDP controlled-release matrix posi- 
tioned at the c#cumferentia] support of a porcine aortic bio- 
prosthesis. Reproduced with permission from Replacement 
Cardiac Valves, Bodnar E. and Frater, R. (Eds.) Pergamon, 
Elmsford, NY, 1988. 
polymer ring with plain polymer base. A typical 
matrix prior to implantation contained 149 _ 8.69 
mg of EHDP. 
In vitro release of EHDP 
The release profiles of EHDP from silicone 
rubber drug delivery matrices were determined by 
calculating the diphosphonate-associated phos- 
phorus (P) depleted from the polymer matrix as a 
function of time using electron microprobe analy- 
sis. Electron microprobe analysis was conducted 
using a Super 8000 Analyst equipped with a Kevex 
(Foster City, CA) system for elemental localiza- 
tion which was coupled with a scanning electron 
microscope (Hitachi, Model S-570, Santa Clara, 
CA). The Super 8000 Analyst and scanning elec- 
tron microscope were acquired under Grant No. 
BSR-83-14092 from the National Science Founda- 
tion. 
Matrices were incubated at 37 °C in 20 ml of a 
physiologic buffer (0.10 M NaC1 in 0.05 M HEPES, 
pH = 7.4) and a center, cross-sectional cut of the 
matrix was obtained at 0, 1, 2, 3, 4, and 5 months. 
The samples taken at the various time points were 
allowed to dry at room temperature before the 
analysis. The samples were mounted on stainless- 
steel stubs and sputter-coated with carbon. Sam- 
ples were analyzed for phosphorus and silicon. 
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Emitted X-rays for each element were collected 
for 1.5 rain. The counts associated with the area 
under a peak for each element were calculated by 
a deconvolution routine contained in the software 
program Quantex 1 (Mykelbust et al., 1979). 
The amount of silicon in the silicone based 
polymers was used to normalize the phosphorus 
depletion by computing the ratio of the counts 
associated with the phosphorus peak to the counts 
observed for the silicon (Si) peak for each sample 
at the above specified time points and were com- 
pared with a series of precisely formulated stan- 
dards of known composition (5%, 10%, 15%, 20%, 
and 30% w/w EHDP in silicone rubber). The 
results obtained by microprobe analysis were also 
correlated with data obtained from parallel radio- 
active in vitro release studies using Na 2[ 14 C]EHDP 
and additional studies in which the decrease in 
weight of the polymer rings was observed with 
time. The solubilized Na 2[ 14 C]EHDP was counted 
for radioactivity on a Beckman liquid scintillation 
counter (model 3801, Berkeley, CA). 
Tricuspid valve replacement in sheep 
Twenty-one sheep (6-7 _+ 3 months, male, Suf- 
folk, 42-46 kg) underwent tricuspid valve replace- 
ment with Hancock I (25 mm) bioprosthetic heart 
valves (Johnson & Johnson Cardiovascular, 
Anaheim, CA). Autoclaved silicone rubber 
matrices were coimplanted with the BHV (John- 
son et al., 1988). The matrices contained 
Na2EHDP, Na2EHDP:CaEHDP (1:1), or no 
drug. Data from two previous control animals 
were also compared with these implants (Levy, 
1987b). Each matrix ring was placed around the 
stent posts of the bioprosthesis directly under the 
sewing cushion. Thus, periannular sewing ring su- 
tures also secured the matrix to the prosthesis. 
Retrieval analysis 
At necropsy, the BHV's were removed and 
examined grossly, photographed, and then radio- 
graphed. A representative section of the valve 
cusp from the free edge to the point of attachment 
on the stent post was immediately fixed in a 
cacodylate-buffered 2.5% glutaraldehyde-2% 
paraformaldehyde solution buffered at pH 7.2 
(Kamovsky, 1965) for 24 h and then dehydrated 
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in graded ethanol solutions prior to embedding in 
glycolmethylmethacrylate (JB-4, Polysciences, 
Warrington, PA). Sections (2-3/~m) were stained 
with hematoxylin and eosin for overall morpho- 
logic analyses and von Kossa's reagent for calcium 
phosphate (Levy et al., 1985b). The remaining 
portion of each cusp was prepared for quantitative 
analysis of calcium using atomic absorption spec- 
troscopy (Levy et al., 1980 and 1983c). The poly- 
meric drug delivery ring was detached from the 
sewing ring of the Hancock I bioprosthetic heart 
valve, weighed, and frozen until electron micro- 
probe analysis. 
Representative specimens of lung, liver, kidney, 
spleen, and myocardial tissue adjacent to the im- 
plant valves were also obtained at necropsy. Since 
systemically administered diphosphonates at doses 
of 15 mg/kg /day  or more cause bone toxicity in 
rats (Levy et al., 1985b and 1987a), the proximal 
femoral head was removed from all control and 
treated sheep at necropsy. All specimens were 
stored in 10% neutral buffered formalin until the 
time of histologic analysis by light microscopy. 
Osmotic-mediated matrix expansion 
EHDP matrices of various compositions were 
formulated to study the effects on swelling of 
sealing 76% of the surface area of the matrices 
with drug-free polymer base, incorporating vary- 
ing initial amounts of EHDP (20% w / w  vs 30% 
w/w), and varying the content of the less soluble 
calcium EHDP coincorporated with Na2EHDP. 
The percent weight increase was monitored as a 
function of time with incubations at 37°C in a 
physiologic buffer (0.10 M NaC1 in 0.05 M HEPES, 
pH = 7.4) and weighing the rings on a laboratory 
balance (Galaxy, Model G400, Florham Park, N J). 
Thermomechanical analysis of polymeric implants 
A Metler thermomechanical analyzer (TMA) 
(Model TMA-40, Heightstown, N J) was used to 
assess elastic properties of the various matrix for- 
mulations by applying standardized loads to linear 
segments of the polymer matrices. The Young's 
modulus (Y) was calculated for Silastic polymer 
(Silastic Q7-4840 and Silastic 382), with and 
without dispersed drug, as well as samples of 
explanted polymeric formulations retrieved after 5 
months of circulatory implantation as part of sheep 
tricuspid valve replacements. 
Results and Discussion 
The present study demonstrated an absence of 
CALC in all EHDP controlled-release treated 
BHV's after 120-150 days (Table 1). However, 
only 2 of 7 non-treated explants were calcified, 
indicating deficiencies in the CALC model for 
testing this approach. Nevertheless, there was 
comparable EHDP release in vitro and in vivo, 
and matrix swelling was minimized through seal- 
ing 76% of the releasing surface with drug-free 
polymer and coincorporation of the poorly soluble 
calcium salt of EHDP. In addition, the Young's 
moduli for explanted matrices containing Na 2 
EHDP dispersed in Silastic Q7-4840 (20% w/w) 
were noted to be less than non-drug containing 
Silastic Q7-4840. 
In vivo results 
Six of the 21 sheep were excluded from the 
study because of perioperative death. However, 
TABLE 1 
In vitro release and in vivo efficacy of  silicone rubber-EHDP 
matrices after 20 weeks in the circulation of  sheep 
D r u g / p o l y m e r  5[ E H D P  5[ E H D P  Tissue Ca 2 + 
formulat ion released released ( t t g / m g )  
in vitro a in vivo b 
Control  
Calcified - - 139 4- 20.8 c 
[2] 
Non-calcified - - 2.07 + 0.27 
[51 
N a 2 E H D P  / 78.64-11.1 79.04-4.82 5.744-1.35 d 
silicone rubber  [6] [5] [5] 
N a - C a E H D P  35.7 4- 7.72 40.4 4- 9.68 2.74 4- 0.64 
(1 : 1) /s i l icone 
rubber  [61 [41 [41 
Nu mb er s  of  determinat ions in parentheses.  
a Determined by  electron microprobe  analysis, Na2114C]EHDP 
release, and reduction in matr ix  weight. 
b Determined by  electron microprobe  analysis. 
c F r o m  Levy et at. (1987b); values are m e a n + S . E . M .  
d Includes 2 cases of bacterial endocarditis at 16 weeks. 
none of the sheep died as a result of prosthetic 
valvular dysfunction. Two additional sheep died 
suddenly at 16 weeks and were noted to have 
bacterial endocarditis. One additional animal was 
excluded from the EHDP controlled-release group 
due to sudden death and subsequent contamina- 
tion of the explant. All of the remaining 12 animals 
(7 treatment, 5 control (2 of the 5 control animals 
are from Levy et al., 1987b)) were electively 
euthanized at 20 weeks. 
None of the explanted BHV with drug delivery 
matrices had detectable CALC as determined by 
radiography, light microscopy, and leaflet Ca 2+ 
analysis with atomic absorption spectroscopy (Ta- 
ble 1). However, only two of the 7 non-treated 
valves, from previous control animals, were calci- 
fied. Nevertheless, animals implanted with EHDP 
matrices demonstrated no detectable diphos- 
phonate-related adverse effects, as determined by 
light microscopy of the femoral epiphyseal bone 
biopsies. 
Although previous work (Levy et al., 1985b and 
c; Golomb et al., 1986a and b) had demonstrated 
that the controlled release of approximately 10-30 
/~g E H D P / d a y / t i s s u e  leaflet (avg. tissue weight 
= 8 mg) was sufficient to inhibit CALC of bovine 
pericardial or porcine aortic tissue implanted sub- 
dermally in rats, it would be expected that larger 
amounts of EHDP would be required when de- 
livered locally in the circulation. Although the 
amount (550-775 /~g EHDP/day )  of EHDP de- 
livered in vivo in the present study was sufficient 
to inhibit BHV CALC (Levy et al., 1987a), ef- 
ficacy could not be definitely assessed due to the 
sporadic calcification noted in the control group 
(Table 1). The present study confirms the large 
variability in the measured calcium leaflet con- 
centration observed by others (Barnhart et al., 
1982a) following tricuspid valve replacement in 
sheep. 
Furthermore, the hemodynamic stresses affect- 
ing the orthotopic valve replacements in the tri- 
cuspid position in the present study might have 
contributed to lack of BHV CALC observed in 
explanted valves. Mitral valve replacements, which 
experience greater circulatory stresses, have been 
shown to calcify more extensively than tricuspid 











i I ! I 
20 40 60 80 
TIME (Days) 
Fig. 2. Typical swelling degree vs time profile for silicone 
rubber-EHDP matrices. (11), Unsealed matrix containing 30% 
w/w Na2EHDP; (E3), sealed matrix containing 30% w/w 
Na2EHDP; (A), unsealed matrix containing 30% w/w Na, 
CaEHDP (1 : 1); (a), sealed matrix containing 30% w/w Na, 
CaEHDP (1 : 1); y = swollen weight/dry weight. 
culation of juvenile sheep (Jones et al., 1986; 
Shemin et al., 1988). 
Osmotic-mediated matrix expansion 
Time-dependent matrix expansion due to 
osmosis-related fluid uptake was reduced in vitro 
by sealing 76% of the surface area of each matrix, 
and was further limited with coincorporation of 
CaEHDP as shown in Fig. 2. 
The characteristic matrix swelling and deswel- 
ling stages reported by others (Di Colo et al., 
1980, 1984, 1986; Carelli et al., 1986) were ob- 
served in the polymeric implants in the present 
study. Previous work by others has demonstrated 
that for water-soluble drugs dispersed in PDMS 
polymers, the extent of matrix swelling, -y, defined 
as the ratio of swollen to dry weight of a matrix 
containing a water-soluble additive, has been used 
to characterize stages of matrix swelling and ma- 
trix deswelling (Di Colo et al., 1980, 1984, and 
1986; Carelli et al., 1986) (Fig. 2). Initially, as 
buffer, water, or physiologic fluids are osmotically 
taken up by the matrix, ), increases. At some point 
in time, the value of 7' plateaus and then begins t o  
decrease resulting in a parabolic curve when 
plotted against time of fluid uptake (Di Colo et 
al., 1980, 1984, and 1986; Carelli et al., 1986). The 
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Fig. 3. Typical in vitro release profiles of EHDP from a 
silicone rubber-EHDP circular drug delivery matrix [30% w/w 
Na, CaEHDP (1:1)] (O), Determination by electron micro- 
probe analysis; (A), determination by incorporation of 
Na2[14C]EHDP; (11), determination by following overall ma- 
trix weight. 
in the present in vitro studies ranged from 4 to 29 
days (Fig. 2). 
Sealed matrices explanted from sheep demon- 
strated osmotic-related swelling comparable to the 
in vitro results. The percent increase in weight of 
explanted sealed polymers were 162% + 34.5 
(Na2EHDP) and 69.5% + 1.35 (Na, CaEHDP) 
compared to 141% (Na2EHDP) and 22.2% (Na, 
CaEHDP) for sealed polymer matrices studied in 
vitro, respectively. 
Controlled release of EHDP 
Matrices containing Na2EHDP and CaEHDP 
(1 : 1) released in vitro less EHDP after 20 weeks 
than did those matrices containing only Na 2 EHDP 
as determined by electron microprobe analysis, 
matrix weight change, and release of Na2[14C] 
EHDP. 
A typical profile of the cumulative percent of 
drug (Na, CaEHDP in Silastic 382 (30% w/w)) 
released in vitro over a 20 week period as de- 
termined by electron microprobe analysis is shown 
in Fig. 3. The 3 sealed areas of an individual 
cross-sectional specimen examined in vitro by 
electron microprobe analysis for EHDP release 
demonstrated background phosphorus levels 
versus time for all EHDP matrix formulations. 
Thus, EHDP release from the matrix formulations 
proceeded in one dimension only. 
In formulations where a 1 : 1 ratio of Na/[14C] 
EHDP:CaEHDP was incorporated in the poly- 
mer, the cumulative percent of Na2114C]EHDP 
released from the matrix following 20 weeks in- 
cubation was in close agreement with the total 
percent of EHDP (Na2EHDP and CaEHDP) re- 
leased as determined by electron microprobe anal- 
ysis. This would suggest that the less soluble 
CaEHDP undergoes a delayed dissolution and 
hence, negligible release from the matrix interior 
in the 20 week period. However, although no 
attempt was made in the present study to precisely 
quantitate the relative ratios of the Na2EHDP 
and CaEHDP that had been released, it can be 
noted in Fig. 3 that Na2EHDP was the salt form 
primarily released from the 1:1 matrix formula- 
tions; the CaEHDP acting as a relatively less 
soluble coexcipient [Na2EHDP's aqueous solubil- 
ity is approximately 1000 times that of CaEHDP 
(Golomb, G., Smith, M., unpublished data)]. The 
relative release rates of sodium EHDP and calcium 
EHDP in the formulation used in the present 
study have been previously described in detail 
(Golomb et al., 1987). 
Previous research has shown that the mecha- 
nism of release for EHDP from silicone rubber 
occurs by absorption of a solvent/fluid into the 
matrix interior resulting in dissolution of the drug 
particles and subsequent diffusion of the drug 
from the polymeric matrix via a network of tortu- 
ous channels and pores created by dissolved drug 
particles (Golomb et al., 1986a; Levy et al., 1985c; 
Bawa et al., 1985). Neither Na2EHDP nor 
CaEHDP are soluble in the hydrophobic silicone 
rubbers used in the present study (Golomb et al., 
1986b and 1987; Levy et al., 1985b and c). De- 
termination of the cumulative percent of EHDP 
released after 20 weeks by calculation of the de- 
crease in matrix weight after drying to a constant 
weight, resulted in an approximate 7-10% under- 
estimation of total drug released compared to the 
percent EHDP released as determined by electron 
microprobe analysis (Fig. 3). Furthermore, it was 
assumed that the reduction in the initial weight of 
the ring, following oven-drying to a constant 
weight to remove buffer, was due to release of the 
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Fig. 4. Elasticity of controlled-release matrices. (o) EHDP-free 
Silastic 382; (O), EHDP-free Silastic Q7-4840; (rq), Na2EHDP 
dispersed in Silastic 382 (20% w/w); (O), Na2EHDP disper- 
sed in Silastic Q7-4840 (20% w/w); (11), Na-CaEHDP (1 : 1) in 
Silastic Q7-4840 (20% w/w); (rq), explanted specimen 1 (20% 
w/w Na2EHDP in Silastic 382); (A), explanted specimen 2 
(20% w/w Na2EHDP in Silastic Q7-4840); (zx), explanted 
specimen 3 (20% w/w Na-CaEHDP in Silastic Q7-4840). 
dispersed active agent(s) and not due to deteriora- 
tion or destruction of the cured silicone rubber 
polymer matrix. 
In vivo explant analysis of EHDP matrices 
using electron microprobe analysis revealed 79.0 
+ 4.82 cumulative percent EHDP released for 
Na2EHDP matrices and 40.4 _+ 9.68 cumulative 
percent EHDP released for matrices containing 
Na-CaEHDP (1 : 1) after 120-150 days. These re- 
sults were comparable to the in vitro data (Table 
1). However, as emphasized above and previously 
(Johnston et al., 1988), matrix CaEHDP would be 
expected to have continued to release for more 
than 2 years using the present formulation. 
Thermomechanical analysis of polymeric implants 
Thermomechanical analysis results revealed that 
the Young's moduli (Y), or slopes of the respective 
stress-strain curves as shown in Fig. 4, of EHDP- 
Silastic matrices were greater than those measured 
in the non-drug containing Silastic samples. How- 
ever, explanted matrices (20% w/w Na2EHDP or 
Na-CaEHDP in Silastic Q7-4840) were demon- 
strated to have values of Y less than non-drug 
loaded Silastic Q7-4840, indicating perhaps, that 
the matrices explanted after 5 months in the circu- 
lation were demonstrating material fatigue. 
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While the greater stresses applied to the matrices 
implanted in the circulation were below the ulti- 
mate failure stress or yield stress, the continuous, 
cyclic stress-strain patterns may have resulted in 
the initiation of cracks or voids in the matrices 
(Schott, 1983; Sperling, 1986). On repeated stress- 
ing, these tiny flaws or cracks might have slowly 
propagated throughout the entire matrix, repre- 
senting sites where ultimate failure or rupture of 
the polymer matrix could potentially occur. Exten- 
sive propagation of cracks or voids would result in 
a low tensile strength or weakening of the polymer 
matrix (Schott, 1983; Sperling, 1986). Weakening 
of the drug-loaded polymer matrix due to exten- 
sive propagation of cracks could potentially give 
rise to lower values of Y for explanted specimens. 
Propagation of cracks or voids in a polymer 
matrix (20% w/w Na 2EHDP in Silastic Q7-4840) 
arising from deformation due to osmotic-related 
swelling of the drug-loaded matrix would be ex- 
pected to result in a much weaker polymer than a 
Silastic Q7-4840 matrix incorporating a 1 : 1 ratio 
of Na-CaEHDP (20% w/w). It can be noted in 
Fig. 4 that the explanted polymer matrices con- 
taining 20% w/w Na-CaEHDP dispersed in Silas- 
tic Q7-4840 had an approximate 20-fold larger 
value of Y than an explanted polymer specimen 
containing 20% w/w Na2EHDP in Silastic Q7- 
4840. Thus, osmotic effects in the latter matrix 
composition may have contributed to an overall 
weakening of drug-loaded polymer matrices im- 
planted in the circulation for 5 months as com- 
pared to non-implanted, control (non-drug loaded) 
Silastic Q7-4840 polymer. 
Strategies to inhibit BHV CALC 
Local, controlled release of diphosphonate into 
BHV implants for use in the circulation represents 
a novel approach to inhibit BI-IV CALC. It has 
been shown that localized, controlled release of 
diphosphonate (EHDP) using a 2-week osmotic 
pumping device (ALZET, Alza Inc., Stanford, CA) 
was effective at inhibiting BHV CALC at a dose 
of 5 mg /kg /day  and was not associated with 
adverse effects (Levy et al., 1985b). 
Once the effectiveness of locally delivered di- 
phosphonate was established, the search for im- 
plant materials (biocompatible polymers) that 
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would achieve a longer therapeutic duration was 
initiated. It was reported that EVA copolymer 
could be used for the controlled release (> 600 h) 
of EHDP in vitro (Levy et al., 1985c). A further 
prolongation in drug delivery at a controlled rate 
has been demonstrated by judicious selection of 
initial drug load and drug solubility by coin- 
corporation of the poorly soluble calcium salt of 
EHDP in polydimethylsiloxane (Golomb et al., 
1986b and 1987). Recent studies have been di- 
rected at still furthering drug delivery by ap- 
propriate membrane coating with non-drug con- 
taining polymer (Golomb et al., 1986b and 1987). 
All of these strategies have been effective in sus- 
taining release of EHDP from various biocompati- 
ble polymeric matrices to inhibit BHV CALC. 
Conclusions 
The present study has demonstrated the novel 
use of controlled release EHDP for inhibition of 
BHV CALC in sheep. Advantage was taken of 
previous work (Golomb et al., 1986b and 1987) 
using the poorly soluble calcium salt of EHDP 
codispersed with Na 2EHDP in Silastic matrices to 
reduce osmotic-mediated matrix expansion and to 
potentially increase the duration of EHDP con- 
trolled release. Although efficacy could not be 
definitely assessed, matrix release in vivo corre- 
sponded with in vitro results, delivering dosages 
known to be efficacious in the rat subdermal 
model of BHV CALC without adverse side effects. 
Osmosis-related matrix swelling was successfully 
limited by surface sealing and coincorporation of 
CaEHDP. The Young's moduli of the explanted 
controlled-release matrices formulated with Silas- 
tic 382 were intermediate between those of drug- 
loaded matrices and drug-free Silastic 382, indicat- 
ing a return to a native viscoelastic state with in 
vivo release. However, explanted controlled re- 
lease matrices fabricated using Silastic Q7-4840 
appeared to have undergone material fatigue and 
weakening of the polymer matrix, especially 
matrices containing 20% w / w  Na2EHDP in Silas- 
tic Q7-4840 where osmosis-related matrix swelling 
might have contributed to the propagation of 
cracks and voids in the polymer matrix. 
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